Drug intelligence / Profile preview

LOX siRNA

Development stage
Preclinical
Lead developer
Sigma Aldrich
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravitreal, Intraperitoneal
01

Overview

LOX siRNA refers to small interfering RNA molecules designed to silence the expression of the lysyl oxidase (LOX) gene or members of the lipoxygenase (LOX) family, such as 5-LOX (ALOX5), 12-LOX (ALOX12), or 15-LOX (ALOX15). In the context of lysyl oxidase, these siRNAs are investigated for their ability to reduce extracellular matrix remodeling, fibrosis, and vascular leakage, with potential applications in diabetic retinopathy and various cancers where LOX overexpression promotes metastasis and epithelial-mesenchymal transition (EMT). In the context of lipoxygenases, LOX siRNAs are used to study and potentially treat inflammatory conditions, atherosclerosis, and oxidative stress by inhibiting the production of leukotrienes and other lipid mediators. These molecules function by inducing the degradation of target mRNA, thereby preventing the translation of the corresponding enzyme.

Other names
lysyl oxidase siRNA5-LOX siRNA12-LOX siRNA12/15-LOX siRNAlipoxygenase siRNA
02

Targets

LOX (Lysyl oxidase)

Beyond the preview

Go deeper on LOX siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LOX siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call